Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

INKT

MiNK Therapeutics Inc

Apr 24 • 04:00PM ET

0.8890

Dollar change +0.0180
Percentage change 2.07	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.65	Insider Own	71.34%	Shs Outstand	34.60M	Perf Week	-2.87%
Market Cap	30.85M	Forward P/E	-	EPS next Y	-0.60	Insider Trans	0.00%	Shs Float	9.95M	Perf Month	-3.12%
Income	-22.46M	PEG	-	EPS next Q	-0.15	Inst Own	2.86%	Short Float	0.49%	Perf Quarter	-0.90%
Sales	0.00M	P/S	-	EPS this Y	13.39%	Inst Trans	32.08%	Short Ratio	0.49	Perf Half Y	-11.08%
Book/sh	-0.52	P/B	-	EPS next Y	-6.33%	ROA	-172.60%	Short Interest	0.05M	Perf Year	-58.84%
Cash/sh	0.10	P/C	9.15	EPS next 5Y	-	ROE	-1238.95%	52W Range	0.75 - 3.34	Perf YTD	-16.92%
Dividend Est.	-	P/FCF	-	EPS past 5Y	2.37%	ROI	-	52W High	-73.38%	Beta	0.10
Dividend TTM	-	Quick Ratio	0.32	Sales past 5Y	-25.00%	Gross Margin	-	52W Low	18.53%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	0.32	EPS Y/Y TTM	21.35%	Oper. Margin	0.00%	RSI (14)	44.94	Volatility	6.90% 12.74%
Employees	31	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.33	Target Price	8.50
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	31.24%	Payout	-	Rel Volume	0.38	Prev Close	0.87
Sales Surprise	-	EPS Surprise	-4.92%	Sales Q/Q	-	Earnings	Mar 21 BMO	Avg Volume	98.05K	Price	0.89
SMA20	-11.47%	SMA50	-7.13%	SMA200	-24.06%	Trades		Volume	38,552	Change	2.07%

Apr-08-24 12:00PM	MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR (GlobeNewswire) -15.38%
Mar-25-24 12:00PM	All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy (Zacks) +5.47%
Mar-22-24 01:25PM	MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-21-24 11:06PM	Q4 2023 Mink Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
11:53AM	INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Loading…
07:00AM	MiNK Reports Fourth Quarter and Year-End 2023 Results (GlobeNewswire)
Mar-07-24 07:30AM	MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report (GlobeNewswire)
Mar-06-24 08:30AM	MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024 (GlobeNewswire)
Feb-14-24 08:00AM	First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK's Allogeneic INKT Cell Therapy and Agenus' Botensilimab and Balstilimab (GlobeNewswire) +7.75%
Feb-06-24 08:00AM	MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications (GlobeNewswire) +10.25%
Jan-30-24 08:00AM	MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene (GlobeNewswire)
Dec-20-23 07:30AM	ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development (GlobeNewswire)
Nov-09-23 08:05AM	MiNK Therapeutics Inc (INKT) Reports Q3 2023 Results: Clinical Progress Amid Financial Challenges (GuruFocus.com) -6.72%
07:00AM	MiNK Therapeutics Reports Third Quarter 2023 Results (GlobeNewswire)
Nov-03-23 12:00PM	MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023 (GlobeNewswire) +13.59%
08:00AM	Loading…
Oct-30-23 08:00AM	MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update (GlobeNewswire) +7.62%
Sep-27-23 09:05AM	MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023 (GlobeNewswire)
Aug-24-23 08:30AM	MiNK Therapeutics to Participate in September Investor Conferences (GlobeNewswire) -8.24%
Aug-10-23 07:30AM	MiNK Therapeutics Reports Second Quarter 2023 Results (GlobeNewswire) +6.67%
Jul-28-23 08:30AM	MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update (GlobeNewswire)
Jun-05-23 07:30AM	MiNK Therapeutics Announces Virtual Annual Shareholders Meeting (GlobeNewswire)
May-22-23 08:30AM	MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference (GlobeNewswire) +16.85%
May-18-23 08:30AM	MiNK's Novel FAP-CAR-iNKT Presented at ASGCT (GlobeNewswire)
May-11-23 08:00AM	MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results (GlobeNewswire) +7.28%
Apr-27-23 08:30AM	MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results (GlobeNewswire) -8.29%
Apr-18-23 01:32PM	MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting (GlobeNewswire)
Apr-16-23 08:03AM	We're Keeping An Eye On MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate (Simply Wall St.)
Apr-04-23 09:55AM	MiNK Therapeutics, Inc. (INKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-30-23 08:41AM	Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics (Business Wire) -6.38%
Mar-29-23 12:00PM	MiNK Therapeutics, Inc. (INKT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
07:36AM	Loading…
Mar-24-23 07:36AM	MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-21-23 08:00AM	MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-15-23 08:45AM	MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting (GlobeNewswire) -5.63%
Mar-07-23 09:00AM	MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +7.35%
Feb-16-23 09:28AM	MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Jan-11-23 02:25PM	MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference (GlobeNewswire)
Dec-22-22 10:49AM	MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2022 Earnings Call Transcript (Insider Monkey)
Nov-17-22 09:00AM	MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference (GlobeNewswire) -5.90%
Nov-10-22 09:05AM	MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline (GlobeNewswire) -12.80%
Nov-06-22 09:39AM	Will MiNK Therapeutics (NASDAQ:INKT) Spend Its Cash Wisely? (Simply Wall St.)
Nov-03-22 08:00AM	MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results (GlobeNewswire) +5.63%
Oct-20-22 09:00AM	MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Oct-05-22 09:16AM	MiNK Therapeutics to Host R&D Event November 10, 2022 (GlobeNewswire) +6.76%
08:30AM	MiNK Selected for Five Presentations at Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
Aug-31-22 09:00AM	MiNK Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire) +14.35%
Aug-16-22 06:16AM	Do Insiders Own Lots Of Shares In MiNK Therapeutics, Inc. (NASDAQ:INKT)? (Simply Wall St.)
Aug-09-22 08:00AM	MiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-02-22 08:30AM	MiNK Therapeutics to Participate at BTIG Biotechnology Conference (GlobeNewswire)
Jul-27-22 08:30AM	MiNK Therapeutics to Report Second Quarter 2022 Financial Results and Business Update (GlobeNewswire) +6.06%
May-25-22 08:30AM	MiNK Therapeutics Announces Virtual Annual Shareholders Meeting (GlobeNewswire)
May-10-22 08:00AM	MiNK Therapeutics Corporate Update and First Quarter 2022 Financial Report (GlobeNewswire) -13.64%
May-09-22 08:43AM	Here's Why We're Not Too Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Situation (Simply Wall St.) -9.74%
Apr-27-22 05:19PM	MiNK Therapeutics to Report First Quarter 2022 Financial Results and Business Update (GlobeNewswire) +15.25%
Mar-18-22 08:30AM	MiNK Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-03-22 04:35PM	MiNK Therapeutics to Report Fourth Quarter & Full Year 2021 Financial Results and Business Update (GlobeNewswire)
09:28AM	MiNK Therapeutics Announces Patients Dosed with AgenT-797 iNKT Cell Therapy in Solid Tumor Cancers (GlobeNewswire)
Mar-01-22 08:00AM	Agenus Corporate Update and Fourth Quarter & Full Year 2021 Financial Report (GlobeNewswire)
Jan-15-22 07:47AM	Could The MiNK Therapeutics, Inc. (NASDAQ:INKT) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Jan-12-22 09:41AM	MiNK Therapeutics to Participate at Upcoming B. Riley Securities Virtual Oncology Conference (GlobeNewswire) +7.69%
Nov-17-21 04:15PM	MiNK Therapeutics to Participate in 4th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +5.01%
Nov-12-21 07:30PM	Agenus inc (AGEN) Q3 2021 Earnings Call Transcript (Motley Fool) -18.12%
07:00AM	MiNK Therapeutics Announces 77% Survival Rate in Intubated Patients with COVID-19 Respiratory Failure Treated with AgenT-797 (GlobeNewswire)
Nov-09-21 08:00AM	MiNK Therapeutics Presents New Preclinical and Clinical Data on iNKT Cell Therapy Programs at SITC 2021 (GlobeNewswire)
08:00AM	Agenus Corporate Update and Third Quarter 2021 Financial Report (GlobeNewswire)
Oct-19-21 04:25PM	MiNK Therapeutics Announces Closing of Initial Public Offering (GlobeNewswire)
Oct-15-21 05:31PM	Paragon 28 Stock Gains in Trading Debut, While MiNK Rebounds (Barrons.com)
Oct-14-21 08:29PM	MiNK Therapeutics, Inc. Announces Pricing of Initial Public Offering (GlobeNewswire)

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AGENUS INC	10% Owner	Oct 16 '23	Buy	1.10	429	472	21,772,863	Oct 16 05:49 PM
AGENUS INC	10% Owner	Oct 13 '23	Buy	1.10	19,373	21,310	21,772,434	Oct 16 05:49 PM
AGENUS INC	10% Owner	Oct 12 '23	Buy	1.10	3,173	3,488	21,753,061	Oct 16 05:49 PM
AGENUS INC	10% Owner	Oct 04 '23	Buy	1.09	15,001	16,380	21,749,888	Oct 06 04:26 PM
AGENUS INC	10% Owner	Aug 29 '23	Buy	1.52	29,678	45,016	21,734,887	Aug 31 05:53 PM
AGENUS INC	10% Owner	Aug 28 '23	Buy	1.45	12,808	18,570	21,705,209	Aug 28 05:15 PM
AGENUS INC	10% Owner	Aug 24 '23	Buy	1.54	170,244	262,908	21,692,401	Aug 28 05:15 PM
AGENUS INC	10% Owner	May 11 '23	Buy	1.43	23,361	33,348	21,640,473	May 12 05:18 PM
AGENUS INC	10% Owner	May 10 '23	Buy	1.51	22,065	33,296	21,617,112	May 12 05:18 PM
AGENUS INC	10% Owner	May 05 '23	Buy	0.95	100,200	95,100	21,595,047	May 05 06:00 PM
ARMEN GARO H	Director	May 05 '23	Sale	0.95	100,000	94,850	1,866,400	May 05 06:27 PM
AGENUS INC	10% Owner	May 04 '23	Buy	1.22	21,473	26,246	21,494,847	May 05 06:00 PM
AGENUS INC	10% Owner	May 03 '23	Buy	1.08	128,689	138,843	21,473,374	May 05 06:00 PM
ARMEN GARO H	Director	May 02 '23	Buy	0.95	100,000	94,850	1,978,010	May 04 07:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INKT

MiNK Therapeutics Inc

Upgrade your FINVIZ experience